[
    [
        {
            "time": "",
            "original_text": "从早期临床到真实世界，我们如何更好迎接中国医药创新的未来？",
            "features": {
                "keywords": [
                    "医药创新",
                    "临床",
                    "真实世界"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "从早期临床到真实世界，我们如何更好迎接中国医药创新的未来？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347.HK)获摩根大通增持9.3467万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "摩根大通",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)获摩根大通增持9.3467万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药被摩根大通减持18.77万股 减持股份数",
            "features": {
                "keywords": [
                    "泰格医药",
                    "摩根大通",
                    "减持"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药被摩根大通减持18.77万股 减持股份数",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347.HK)被摩根大通减持18.7747万股 减持股份数",
            "features": {
                "keywords": [
                    "泰格医药",
                    "摩根大通",
                    "减持"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)被摩根大通减持18.7747万股 减持股份数",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "北向资金再度加仓超36亿，东方财富本周净买入近28亿",
            "features": {
                "keywords": [
                    "北向资金",
                    "加仓",
                    "东方财富"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金再度加仓超36亿，东方财富本周净买入近28亿",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药板块2021Q3分析暨11月月报：高基数下增速放缓 板块基本面依旧强劲 把握配置窗口期",
            "features": {
                "keywords": [
                    "医药板块",
                    "2021Q3",
                    "增速放缓",
                    "基本面强劲"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药板块2021Q3分析暨11月月报：高基数下增速放缓 板块基本面依旧强劲 把握配置窗口期",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "【最全】2022年中国医药研发外包(CRO)行业上市公司全方位对比(附业务布局汇总、业绩对比、业务规划等)",
            "features": {
                "keywords": [
                    "医药研发外包",
                    "CRO",
                    "上市公司",
                    "业务布局",
                    "业绩对比"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【最全】2022年中国医药研发外包(CRO)行业上市公司全方位对比(附业务布局汇总、业绩对比、业务规划等)",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]